{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:34:57Z","timestamp":1768037697849,"version":"3.49.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04501\/2020"],"award-info":[{"award-number":["UIDB\/04501\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/136904\/2018"],"award-info":[{"award-number":["SFRH\/BD\/136904\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["IF\/00286\/2015"],"award-info":[{"award-number":["IF\/00286\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2022\/10080\/BD"],"award-info":[{"award-number":["2022\/10080\/BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"Fundo Europeu de Desenvolvimento Regional","doi-asserted-by":"crossref","award":["POCI-01-0145-FEDER-007628"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007628"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007689","name":"Universidade de Aveiro","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007689","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Galectin-3 (Gal-3) belongs to galectin protein family, a type of \u03b2-galactose-binding lectin having more than one evolutionarily conserved domain of carbohydrate recognition. Gal-3 is mainly located in the cytoplasm, but it also enters the nucleus and is secreted into the extracellular environment and biological fluids such as urine, saliva, and serum. It plays an important role in many biological functions, such as angiogenesis, apoptosis, cell differentiation, cell growth, fibrosis, inflammation, host defense, cellular modification, splicing of pre-mRNA, and transformation. Many previous studies have shown that Gal-3 can be used as a diagnostic or prognostic biomarker for heart ailments, kidney diseases, and other major illnesses including cancer. Moreover, it may also play a major role in risk stratification in different diseases, and in this review, we have summarized the potential roles and application of Gal-3 as diagnostic, prognostic, and risk stratifying biomarker from previously reported studies in heart diseases and cancer, with special emphasis on prostate cancer.<\/jats:p>","DOI":"10.1007\/s11033-022-08207-1","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T06:02:20Z","timestamp":1672380140000},"page":"2763-2778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Galectin-3 in prostate cancer and heart diseases: a biomarker for these two frightening pathologies?"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-6697","authenticated-orcid":false,"given":"T\u00e2nia","family":"Lima","sequence":"first","affiliation":[]},{"given":"Lu\u00eds","family":"Perp\u00e9tuo","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Fardilha","sequence":"additional","affiliation":[]},{"given":"Adelino","family":"Leite-Moreira","sequence":"additional","affiliation":[]},{"given":"Jose","family":"Bastos","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Vitorino","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"8207_CR1","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH (2016) Shared risk factors in cardiovascular disease and cancer. Circulation 133:1104\u20131114. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.020406","journal-title":"Circulation"},{"key":"8207_CR2","doi-asserted-by":"publisher","first-page":"e000666","DOI":"10.1136\/openhrt-2017-000666","volume":"5","author":"T Kamai","year":"2018","unstructured":"Kamai T, Tokura Y, Uematsu T et al (2018) Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer. Open Hear 5:e000666. https:\/\/doi.org\/10.1136\/openhrt-2017-000666","journal-title":"Open Hear"},{"key":"8207_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ijcard.2015.10.127","volume":"203","author":"M Behnes","year":"2016","unstructured":"Behnes M, Bertsch T, Weiss C et al (2016) Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients. Int J Cardiol 203:398\u2013406. https:\/\/doi.org\/10.1016\/j.ijcard.2015.10.127","journal-title":"Int J Cardiol"},{"key":"8207_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/pros.20688","volume":"68","author":"AS Merseburger","year":"2008","unstructured":"Merseburger AS, Kramer MW, Hennenlotter J et al (2008) Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate 68:72\u201377. https:\/\/doi.org\/10.1002\/pros.20688","journal-title":"Prostate"},{"key":"8207_CR5","first-page":"839","volume":"11","author":"J Gao","year":"2018","unstructured":"Gao J, Li T, Mo Z et al (2018) Overexpression of the galectin-3 during tumor progression in prostate cancer and its clinical implications. Int J Clin Exp Pathol 11:839\u2013846","journal-title":"Int J Clin Exp Pathol"},{"key":"8207_CR6","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/molbev\/msh082","volume":"21","author":"D Houzelstein","year":"2004","unstructured":"Houzelstein D, Gon\u00e7alves IR, Fadden AJ et al (2004) Phylogenetic analysis of the vertebrate galectin family. Mol Biol Evol 21:1177\u20131187. https:\/\/doi.org\/10.1093\/molbev\/msh082","journal-title":"Mol Biol Evol"},{"key":"8207_CR7","first-page":"6239","volume":"59","author":"HC Gong","year":"1999","unstructured":"Gong HC, Honjo Y, Nangia-Makker P et al (1999) The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 59:6239\u20136245","journal-title":"Cancer Res"},{"key":"8207_CR8","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1074\/jbc.C111.331686","volume":"287","author":"V Balan","year":"2012","unstructured":"Balan V, Nangia-Makker P, Kho DH et al (2012) Tyrosine-phosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage. J Biol Chem 287:5192\u20135198. https:\/\/doi.org\/10.1074\/jbc.C111.331686","journal-title":"J Biol Chem"},{"key":"8207_CR9","first-page":"5272","volume":"57","author":"S Akahani","year":"1997","unstructured":"Akahani S, Nangia-Makker P, Inohara H et al (1997) Galectin-3: A novel antiapoptotic molecule with A functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57:5272\u20135276","journal-title":"Cancer Res"},{"key":"8207_CR10","doi-asserted-by":"publisher","first-page":"7546","DOI":"10.1158\/0008-5472.CAN-05-1197","volume":"65","author":"N Oka","year":"2005","unstructured":"Oka N, Nakahara S, Takenaka Y et al (2005) Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res 65:7546\u20137553. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1197","journal-title":"Cancer Res"},{"key":"8207_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0006-291X(03)00151-7","volume":"302","author":"I Paron","year":"2003","unstructured":"Paron I, Scaloni A, Pines A et al (2003) Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun 302:545\u2013553. https:\/\/doi.org\/10.1016\/S0006-291X(03)00151-7","journal-title":"Biochem Biophys Res Commun"},{"key":"8207_CR12","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1158\/0008-5472.CAN-05-0104","volume":"65","author":"T Shimura","year":"2005","unstructured":"Shimura T, Takenaka Y, Fukumori T et al (2005) Implication of galectin-3 in Wnt signaling. Cancer Res 65:3535\u20133537. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0104","journal-title":"Cancer Res"},{"key":"8207_CR13","doi-asserted-by":"publisher","first-page":"49484","DOI":"10.16832\/oncotarget.17718","volume":"8","author":"SN Dos Santos","year":"2017","unstructured":"Dos Santos SN, Sheldon H, Pereira JX et al (2017) Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1\/Notch activation. Oncotarget 8:49484\u201349501. https:\/\/doi.org\/10.16832\/oncotarget.17718","journal-title":"Oncotarget"},{"key":"8207_CR14","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1158\/1535-7163.MCT-10-0262","volume":"9","author":"R Levy","year":"2010","unstructured":"Levy R, Grafi-Cohen M, Kraiem Z, Kloog Y (2010) Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. Mol Cancer Ther 9:2208\u20132219. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0262","journal-title":"Mol Cancer Ther"},{"key":"8207_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105144","author":"A Sedl\u00e1\u0159","year":"2021","unstructured":"Sedl\u00e1\u0159 A, Tr\u00e1vn\u00ed\u010dkov\u00e1 M, Bojarov\u00e1 P et al (2021) Interaction between Galectin-3 and integrins mediates cell-matrix adhesion in endothelial cells and mesenchymal stem cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22105144","journal-title":"Int J Mol Sci"},{"key":"8207_CR16","doi-asserted-by":"publisher","first-page":"39649","DOI":"10.1074\/jbc.M608069200","volume":"281","author":"S Nakahara","year":"2006","unstructured":"Nakahara S, Hogan V, Inohara H, Raz A (2006) Importin-mediated nuclear translocation of galectin-3. J Biol Chem 281:39649\u201339659. https:\/\/doi.org\/10.1074\/jbc.M608069200","journal-title":"J Biol Chem"},{"issue":"149\u2013157","key":"8207_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.11072","volume":"105","author":"J Mollenhauer","year":"2003","unstructured":"Mollenhauer J, Deichmann M, Helmke B, M\u00fcller H, Kollender G, Holmskov U, Ligtenberg T, Krebs I, Wiemann S, Bantel-Schaal U, Madsen J, Bikker F, Klauck SM, Otto HF, Moldenhauer G, Poustka A (2003) Frequent downregulation of DMBT1 and galectin-3 in epithelial skin cancer. Int J canc 105(149\u2013157):1. https:\/\/doi.org\/10.1002\/ijc.11072","journal-title":"Int J canc"},{"key":"8207_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3233\/CBM-160661","volume":"17","author":"Z Huang","year":"2016","unstructured":"Huang Z, Ai Z, Li N et al (2016) Over expression of galectin-3 associates with short-term poor prognosis in stage II colon cancer. Cancer Biomark 17:445\u2013455. https:\/\/doi.org\/10.3233\/CBM-160661","journal-title":"Cancer Biomark"},{"key":"8207_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/1097-0045(20000701)44:2<118::AID-PROS4>3.0.CO;2-U","volume":"44","author":"RA Pacis","year":"2000","unstructured":"Pacis RA, Pilat MJ, Pienta KJ et al (2000) Decreased galectin-3 expression in prostate cancer. Prostate 44:118\u2013123. https:\/\/doi.org\/10.1002\/1097-0045(20000701)44:2%3c118::AID-PROS4%3e3.0.CO;2-U","journal-title":"Prostate"},{"key":"8207_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3892\/ijo.17.2.271","volume":"17","author":"XC Xu","year":"2000","unstructured":"Xu XC, Sola Gallego JJ, Lotan R, El-Naggar AK (2000) Differential expression of galectin-1 and galectin-3 in benign and malignant salivary gland neoplasms. Int J Oncol 17:271\u2013276. https:\/\/doi.org\/10.3892\/ijo.17.2.271","journal-title":"Int J Oncol"},{"key":"8207_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00432-012-1178-2","volume":"138","author":"L Xie","year":"2012","unstructured":"Xie L, Chen WNX, Song BC et al (2012) The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol 138:1035\u20131043. https:\/\/doi.org\/10.1007\/s00432-012-1178-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"8207_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00345-008-0294-8","volume":"26","author":"AS Merseburger","year":"2008","unstructured":"Merseburger AS, Kramer \u00c6MW, Hennenlotter J et al (2008) Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol 26:637\u2013642. https:\/\/doi.org\/10.1007\/s00345-008-0294-8","journal-title":"World J Urol"},{"key":"8207_CR23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/hupa.2001.22767","volume":"32","author":"T Shimonishi","year":"2001","unstructured":"Shimonishi T, Miyazaki K, Kono N et al (2001) Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 32:302\u2013310. https:\/\/doi.org\/10.1053\/hupa.2001.22767","journal-title":"Hum Pathol"},{"key":"8207_CR24","doi-asserted-by":"publisher","first-page":"6452","DOI":"10.1073\/pnas.84.18.6452","volume":"84","author":"IK Moutsatsos","year":"1987","unstructured":"Moutsatsos IK, Wade M, Schindler M, Wang JL (1987) Endogenous lectins from cultured cells: nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci USA 84:6452\u20136456. https:\/\/doi.org\/10.1073\/pnas.84.18.6452","journal-title":"Proc Natl Acad Sci USA"},{"key":"8207_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jaut.2017.11.002","volume":"89","author":"ZR Shi","year":"2018","unstructured":"Shi ZR, Tan GZ, Cao CX et al (2018) Decrease of galectin-3 in keratinocytes: a potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis. J Autoimmun 89:30\u201340. https:\/\/doi.org\/10.1016\/j.jaut.2017.11.002","journal-title":"J Autoimmun"},{"key":"8207_CR26","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1523\/jneurosci.14-05-03231.1994","volume":"14","author":"F Reichert","year":"1994","unstructured":"Reichert F, Saada A, Rotshenker S (1994) Peripheral nerve injury induces Schwann cells to express two macrophage phenotypes: phagocytosis and the galactose-specific lectin MAC-2. J Neurosci 14:3231\u20133245. https:\/\/doi.org\/10.1523\/jneurosci.14-05-03231.1994","journal-title":"J Neurosci"},{"key":"8207_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.12659\/MSM.892386","volume":"21","author":"B Liang","year":"2015","unstructured":"Liang B (2015) Serum Galectin-3 as a potential marker for gastric cancer. Med Sci Monit Med J Exp Clin Res 21:755\u2013760. https:\/\/doi.org\/10.12659\/MSM.892386","journal-title":"Med Sci Monit Med J Exp Clin Res"},{"key":"8207_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1189\/jlb.69.4.555","volume":"69","author":"HG Joo","year":"2001","unstructured":"Joo HG, Goedegebuure PS, Sadanaga N et al (2001) Expression and function of galectin-3, a \u03b2-galactoside-binding protein in activated T lymphocytes. J Leukoc Biol 69:555\u2013564. https:\/\/doi.org\/10.1189\/jlb.69.4.555","journal-title":"J Leukoc Biol"},{"key":"8207_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.7150\/ijms.8083","volume":"11","author":"YY Chang","year":"2014","unstructured":"Chang YY, Chen A, Wu XM et al (2014) Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure. Int J Med Sci 11:1098\u20131106. https:\/\/doi.org\/10.7150\/ijms.8083","journal-title":"Int J Med Sci"},{"key":"8207_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","volume":"99","author":"DJA Lok","year":"2010","unstructured":"Lok DJA, Van Der Meer P, De La Porte PWBA et al (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99:323\u2013328. https:\/\/doi.org\/10.1007\/s00392-010-0125-y","journal-title":"Clin Res Cardiol"},{"key":"8207_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3909\/ricm0624","volume":"12","author":"PA McCullough","year":"2011","unstructured":"McCullough PA, Olobatoke A, Vanhecke TE (2011) Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 12:200\u2013210. https:\/\/doi.org\/10.3909\/ricm0624","journal-title":"Rev Cardiovasc Med"},{"key":"8207_CR32","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","volume":"60","author":"JE Ho","year":"2012","unstructured":"Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Martin G, Larson DL (2012) Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60:1249\u20131256. https:\/\/doi.org\/10.1016\/j.jacc.2012.04.053","journal-title":"J Am Coll Cardiol"},{"key":"8207_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00392-019-01557-0","volume":"109","author":"X Zhang","year":"2020","unstructured":"Zhang X, Karunathilaka N, Senanayake S et al (2020) The potential prognostic utility of salivary galectin-3 concentrations in heart failure. Clin Res Cardiol 109:685\u2013692. https:\/\/doi.org\/10.1007\/s00392-019-01557-0","journal-title":"Clin Res Cardiol"},{"key":"8207_CR34","doi-asserted-by":"publisher","first-page":"18401","DOI":"10.1016\/S0021-9258(17)32322-0","volume":"269","author":"A Ullrich","year":"1994","unstructured":"Ullrich A, Sures I, D\u2019Egidio M et al (1994) The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 269:18401\u201318407","journal-title":"J Biol Chem"},{"key":"8207_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ijc.23970","volume":"124","author":"N Tinari","year":"2009","unstructured":"Tinari N, Lattanzio R, Querzoli P et al (2009) High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. Int J Cancer 124:333\u2013338. https:\/\/doi.org\/10.1002\/ijc.23970","journal-title":"Int J Cancer"},{"key":"8207_CR36","first-page":"2535","volume":"62","author":"A Marchetti","year":"2002","unstructured":"Marchetti A, Tinari N, Buttitta F et al (2002) Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 62:2535\u20132539","journal-title":"Cancer Res"},{"key":"8207_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-015-0606-x","volume":"13","author":"E Piccolo","year":"2015","unstructured":"Piccolo E, Tinari N, D\u2019Addario D et al (2015) Prognostic relevance of LGALS3BP in human colorectal carcinoma. J Transl Med 13:1\u20139. https:\/\/doi.org\/10.1186\/s12967-015-0606-x","journal-title":"J Transl Med"},{"key":"8207_CR38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/pros.20343","volume":"66","author":"EL Bair","year":"2006","unstructured":"Bair EL, Nagle RB, Ulmer TA et al (2006) 90K\/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate 66:283\u2013293. https:\/\/doi.org\/10.1002\/pros.20343","journal-title":"Prostate"},{"key":"8207_CR39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.hlc.2015.08.021","volume":"25","author":"K Zhou","year":"2016","unstructured":"Zhou K, Zhou Y, Zhao Y et al (2016) The Relationship between Galectin-3 and different patterns of ventricular geometry remodelling in aortic valve stenosis. Heart Lung Circ 25:371\u2013377. https:\/\/doi.org\/10.1016\/j.hlc.2015.08.021","journal-title":"Heart Lung Circ"},{"key":"8207_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2546-0","volume":"16","author":"K Fritsch","year":"2016","unstructured":"Fritsch K, Mernberger M, Nist A et al (2016) Galectin-3 interacts with components of the nuclear ribonucleoprotein complex. BMC Cancer 16:1\u201310. https:\/\/doi.org\/10.1186\/s12885-016-2546-0","journal-title":"BMC Cancer"},{"key":"8207_CR41","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1210\/en.2004-0506","volume":"145","author":"A Grassadonia","year":"2004","unstructured":"Grassadonia A, Tinari N, Fiorentino B et al (2004) The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, \u03b3-interferon, and double-strand polynucleotides. Endocrinology 145:4728\u20134736. https:\/\/doi.org\/10.1210\/en.2004-0506","journal-title":"Endocrinology"},{"key":"8207_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000026","author":"CT Nielsen","year":"2014","unstructured":"Nielsen CT, Lood C, \u00d8stergaard O et al (2014) Plasma levels of galectin-3-binding protein reflect type i interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2014-000026","journal-title":"Lupus Sci Med"},{"key":"8207_CR43","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2014-04-569939","volume":"125","author":"EP DeRoo","year":"2015","unstructured":"DeRoo EP, Wrobleski SK, Shea EM et al (2015) The role of galectin-3 and galectin-3-binding protein in venous thrombosis. Blood 125:1813\u20131821. https:\/\/doi.org\/10.1182\/blood-2014-04-569939","journal-title":"Blood"},{"key":"8207_CR44","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/art.38065","volume":"65","author":"O \u00d8stergaard","year":"2013","unstructured":"\u00d8stergaard O, Nielsen CT, Iversen LV et al (2013) Unique protein signature of circulating microparticles in systemic lupus erythematosus. Arthritis Rheum 65:2680\u20132690. https:\/\/doi.org\/10.1002\/art.38065","journal-title":"Arthritis Rheum"},{"key":"8207_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2010.01.019","volume":"125","author":"E Ramacciotti","year":"2010","unstructured":"Ramacciotti E, Hawley AE, Wrobleski SK et al (2010) Proteomics of microparticles after deep venous thrombosis. Thromb Res 125:1\u201316. https:\/\/doi.org\/10.1016\/j.thromres.2010.01.019","journal-title":"Thromb Res"},{"key":"8207_CR46","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1128\/mcb.24.10.4395-4406.2004","volume":"24","author":"Y Takenaka","year":"2004","unstructured":"Takenaka Y, Fukumori T, Yoshii T et al (2004) Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 24:4395\u20134406. https:\/\/doi.org\/10.1128\/mcb.24.10.4395-4406.2004","journal-title":"Mol Cell Biol"},{"key":"8207_CR47","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1074\/jbc.M107668200","volume":"277","author":"T Yoshii","year":"2002","unstructured":"Yoshii T, Fukumori T, Honjo Y et al (2002) Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 277:6852\u20136857. https:\/\/doi.org\/10.1074\/jbc.M107668200","journal-title":"J Biol Chem"},{"key":"8207_CR48","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.bbamcr.2010.06.007","volume":"1803","author":"V Balan","year":"2011","unstructured":"Balan V, Nangia-Makker P, Jung YS, Wang Y, Raz A (2011) Galectin-3: a novel substrate for c-Abl kinase. Biochim Biophys Acta 1803:1198\u20131205. https:\/\/doi.org\/10.1016\/j.bbamcr.2010.06.007","journal-title":"Biochim Biophys Acta"},{"key":"8207_CR49","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1158\/0008-5472.CAN-15-1793","volume":"76","author":"K Nakajima","year":"2016","unstructured":"Nakajima K, Kho DH, Yanagawa T et al (2016) Galectin-3 cleavage alters bone remodeling: different outcomes in breast and prostate cancer skeletal metastasis. Cancer Res 76:1391\u20131402. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1793","journal-title":"Cancer Res"},{"key":"8207_CR50","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/ijc.25254","volume":"127","author":"P Nangia-Makker","year":"2010","unstructured":"Nangia-Makker P, Wang Y, Raz T et al (2010) Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 127:2530\u20132541. https:\/\/doi.org\/10.1002\/ijc.25254","journal-title":"Int J Cancer"},{"key":"8207_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/pros.21236","volume":"71","author":"S Saraswati","year":"2011","unstructured":"Saraswati S, Block AS, Davidson MK, Rank RG, Maha Mahadevan ABD (2011) Galectin-3 is a substrate for prostate specific antigen (PSA) in human seminal plasma. Prostate 71:197\u2013208. https:\/\/doi.org\/10.1002\/pros.21236","journal-title":"Prostate"},{"key":"8207_CR52","doi-asserted-by":"publisher","first-page":"21337","DOI":"10.1074\/jbc.M608810200","volume":"282","author":"N Mazurek","year":"2007","unstructured":"Mazurek N, Yun JS, Liu KF et al (2007) Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells. J Biol Chem 282:21337\u201321348. https:\/\/doi.org\/10.1074\/jbc.M608810200","journal-title":"J Biol Chem"},{"key":"8207_CR53","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1002\/cncr.26078","volume":"117","author":"N Mazurek","year":"2011","unstructured":"Mazurek N, Byrd JC, Sun Y et al (2011) A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer 117:4375\u20134380. https:\/\/doi.org\/10.1002\/cncr.26078","journal-title":"Cancer"},{"key":"8207_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2011.09.003","volume":"313","author":"AU Newlaczyl","year":"2011","unstructured":"Newlaczyl AU, Yu L (2011) Galectin-3 \u2013 A jack-of-all-trades in cancer. Cancer Lett 313:123\u2013128. https:\/\/doi.org\/10.1016\/j.canlet.2011.09.003","journal-title":"Cancer Lett"},{"key":"8207_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.01.019","author":"L Song","year":"2014","unstructured":"Song L, Tang J-W, Owusu L et al (2014) Galectin-3 in cancer. Clin Chim Acta. https:\/\/doi.org\/10.1016\/j.cca.2014.01.019","journal-title":"Clin Chim Acta"},{"key":"8207_CR56","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.prp.2017.01.012","volume":"213","author":"J Al-maghrabi","year":"2017","unstructured":"Al-maghrabi J, Shafie A, Ghabrah T (2017) Immunohistochemical expression of galectin-3 is significantly associated with grade, stage and differentiation of endometrial carcinomas. Pathol Res Pract 213:348\u2013352. https:\/\/doi.org\/10.1016\/j.prp.2017.01.012","journal-title":"Pathol Res Pract"},{"key":"8207_CR57","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12967-014-0273-3","volume":"12","author":"S-S Jiang","year":"2014","unstructured":"Jiang S-S, Weng D-S, Wang Q-J et al (2014) Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med 12:273. https:\/\/doi.org\/10.1186\/s12967-014-0273-3","journal-title":"J Transl Med"},{"key":"8207_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000365673","volume":"7","author":"GH El","year":"2014","unstructured":"El GH, Madkour B, Abdelaty S et al (2014) Diagnostic and prognostic significance of serum and tissue galectin 3 expression in patients with carcinoma of the bladder. Curr Urol 7:185\u2013190. https:\/\/doi.org\/10.1159\/000365673","journal-title":"Curr Urol"},{"key":"8207_CR59","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.3390\/cancers13194819","volume":"13","author":"BB Blair","year":"2021","unstructured":"Blair BB, Funkhouser AT, Goodwin JL et al (2021) Increased circulating levels of galectin proteins in patients with breast, colon, and lung cancer. Cancers (Basel) 13:4819. https:\/\/doi.org\/10.3390\/cancers13194819","journal-title":"Cancers (Basel)"},{"key":"8207_CR60","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/biomedicines10020352","volume":"10","author":"TM Okda","year":"2022","unstructured":"Okda TM, Atwa GMK, Eldehn AF et al (2022) A Novel role of galectin-3 and thyroglobulin in prognosis and differentiation of different stages of thyroid cancer and elucidation of the potential contribution of Bcl-2, IL-8. Biomedicines 10:352. https:\/\/doi.org\/10.3390\/biomedicines10020352","journal-title":"Biomedicines"},{"key":"8207_CR61","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/1097-0215(20000720)89:4<361::aid-ijc8>3.3.co;2-l","volume":"89","author":"FA Van Den Br\u00fble","year":"2000","unstructured":"Van Den Br\u00fble FA, Waltregny D, Liu FT, Castronovo V (2000) Alteration of the cytoplasmic\/nuclear expression pattern of Galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89:361\u2013367. https:\/\/doi.org\/10.1002\/1097-0215(20000720)89:4%3c361::aid-ijc8%3e3.3.co;2-l","journal-title":"Int J Cancer"},{"key":"8207_CR62","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3892\/ijo.12.6.1287","volume":"12","author":"H Idikio","year":"1998","unstructured":"Idikio H (1998) Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12:1287\u20131290. https:\/\/doi.org\/10.3892\/ijo.12.6.1287","journal-title":"Int J Oncol"},{"key":"8207_CR63","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/S0016-5085(97)70010-6","volume":"113","author":"X Sanjuan","year":"1997","unstructured":"Sanjuan X, Fernandez PL, Castells A et al (1997) Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 113:1906\u20131915. https:\/\/doi.org\/10.1016\/S0016-5085(97)70010-6","journal-title":"Gastroenterology"},{"key":"8207_CR64","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"8207_CR65","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1038\/sj.onc.1207997","volume":"23","author":"S Califice","year":"2004","unstructured":"Califice S, Castronovo V, Bracke M, van den Br\u00fble F (2004) Dual activities of galectin-3 in human prostate cancer\u202f: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23:7527\u20137536. https:\/\/doi.org\/10.1038\/sj.onc.1207997","journal-title":"Oncogene"},{"key":"8207_CR66","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1158\/0008-5472.CAN-05-3750","volume":"66","author":"T Fukumori","year":"2006","unstructured":"Fukumori T, Oka N, Takenaka Y et al (2006) Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 66:3114\u20133119. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3750","journal-title":"Cancer Res"},{"key":"8207_CR67","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1593\/tlo.09118","volume":"2","author":"H Ahmed","year":"2009","unstructured":"Ahmed H, Cappello F, Rodolico V, Vasta GR (2009) Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol 2:146\u2013156. https:\/\/doi.org\/10.1593\/tlo.09118","journal-title":"Transl Oncol"},{"key":"8207_CR68","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bbrc.2007.04.114","volume":"358","author":"H Ahmed","year":"2007","unstructured":"Ahmed H, Banerjee PP, Vasta GR (2007) Differential expression of galectins in normal, benign and malignant prostate epithelial cells: Silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun 358:241\u2013246. https:\/\/doi.org\/10.1016\/j.bbrc.2007.04.114","journal-title":"Biochem Biophys Res Commun"},{"key":"8207_CR69","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1007\/s12010-009-8753-2","volume":"160","author":"M Ribeiro De Melo-J\u00fanior","year":"2010","unstructured":"Ribeiro De Melo-J\u00fanior M, Luiz J, Ara\u00fajo-Filho S et al (2010) Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis. Appl Biochem Biotechnol 160:2198\u20132207. https:\/\/doi.org\/10.1007\/s12010-009-8753-2","journal-title":"Appl Biochem Biotechnol"},{"key":"8207_CR70","doi-asserted-by":"publisher","first-page":"542","DOI":"10.18632\/oncotarget.923","volume":"4","author":"V Balan","year":"2013","unstructured":"Balan V, Wang Y, Nangia-Makker P et al (2013) Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget 4:542\u2013549. https:\/\/doi.org\/10.18632\/oncotarget.923","journal-title":"Oncotarget"},{"key":"8207_CR71","doi-asserted-by":"publisher","first-page":"82266","DOI":"10.18632\/oncotarget.12619","volume":"7","author":"K Nakajima","year":"2016","unstructured":"Nakajima K, Heilbrun LK, Hogan V et al (2016) Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I. Oncotarget 7:82266\u201382272","journal-title":"Oncotarget"},{"key":"8207_CR72","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/454256","author":"C Geisler","year":"2015","unstructured":"Geisler C, Gaisa NT, Pfister D et al (2015) Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. Biomed Res Int. https:\/\/doi.org\/10.1155\/2015\/454256","journal-title":"Biomed Res Int"},{"key":"8207_CR73","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1021\/acs.jproteome.1c00763","volume":"21","author":"T Lima","year":"2022","unstructured":"Lima T, Ferreira R, Freitas M et al (2022) Integration of automatic text mining and genomic and proteomic analysis to unravel prostate cancer biomarkers. J Proteome Res 21:447\u2013458. https:\/\/doi.org\/10.1021\/acs.jproteome.1c00763","journal-title":"J Proteome Res"},{"key":"8207_CR74","first-page":"1323","volume":"12","author":"QK Li","year":"2022","unstructured":"Li QK, Lih TM, Wang Y et al (2022) Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels. Am J Cancer Res 12:1323\u20131336","journal-title":"Am J Cancer Res"},{"key":"8207_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.277","author":"Y Wang","year":"2013","unstructured":"Wang Y, Balan V, Gao X et al (2013) The significance of galectin-3 as a new basal cell marker in prostate cancer. Cell Death Dis. https:\/\/doi.org\/10.1038\/cddis.2013.277","journal-title":"Cell Death Dis"},{"key":"8207_CR76","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s002400050164","volume":"27","author":"J Ellerhorst","year":"1999","unstructured":"Ellerhorst J, Troncoso P, Xu XC et al (1999) Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res 27:362\u2013367","journal-title":"Urol Res"},{"key":"8207_CR77","first-page":"1861","volume":"6","author":"JL Ara\u00fajo-Filho","year":"2013","unstructured":"Ara\u00fajo-Filho JL, Melo-Junior MR, Beltr\u00e3o EIC et al (2013) Immunochemiluminescent detection of galectin-3 in tumoral tissue from prostate. Int J Clin Exp Pathol 6:1861\u20131867","journal-title":"Int J Clin Exp Pathol"},{"key":"8207_CR78","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2353\/ajpath.2009.080816","volume":"174","author":"Y Wang","year":"2009","unstructured":"Wang Y, Nangia-makker P, Tait L et al (2009) Regulation of prostate cancer progression by galectin-3. Am J Pathol 174:1515\u20131523. https:\/\/doi.org\/10.2353\/ajpath.2009.080816","journal-title":"Am J Pathol"},{"key":"8207_CR79","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-012-0925-y","author":"JS Knapp","year":"2012","unstructured":"Knapp JS, Lokeshwar SD et al (2012) Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence. World J Urol. https:\/\/doi.org\/10.1007\/s00345-012-0925-y","journal-title":"World J Urol"},{"key":"8207_CR80","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12619","author":"K Nakajima","year":"2016","unstructured":"Nakajima K, Heilbrun LK, Hogan V et al (2016) Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.12619","journal-title":"Oncotarget"},{"key":"8207_CR81","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","volume":"110","author":"UC Sharma","year":"2004","unstructured":"Sharma UC, Pokharel S, Van Brakel TJ et al (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121\u20133128. https:\/\/doi.org\/10.1161\/01.CIR.0000147181.65298.4D","journal-title":"Circulation"},{"key":"8207_CR82","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1152\/ajpheart.00747.2008","volume":"296","author":"YH Liu","year":"2009","unstructured":"Liu YH, D\u2019Ambrosio M, Liao TD et al (2009) N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion\/growth-regulatory lectin. Am J Physiol Hear Circ Physiol 296:404\u2013412. https:\/\/doi.org\/10.1152\/ajpheart.00747.2008","journal-title":"Am J Physiol Hear Circ Physiol"},{"key":"8207_CR83","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","volume":"48","author":"RR van Kimmenade","year":"2006","unstructured":"van Kimmenade RR, Januzzi JL, Ellinor PT et al (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48:1217\u20131224. https:\/\/doi.org\/10.1016\/j.jacc.2006.03.061","journal-title":"J Am Coll Cardiol"},{"key":"8207_CR84","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1093\/eurheartj\/ehs077","volume":"33","author":"L Gullestad","year":"2012","unstructured":"Gullestad L, Ueland T, Kjekshus J et al (2012) Galectin-3 predicts response to statin therapy in the controlled rosuvastatin multinational trial in heart failure (CORONA). Eur Heart J 33:2290\u20132296. https:\/\/doi.org\/10.1093\/eurheartj\/ehs077","journal-title":"Eur Heart J"},{"key":"8207_CR85","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.cardfail.2014.07.018","volume":"20","author":"CM Stolen","year":"2014","unstructured":"Stolen CM, Adourian A, Meyer TE et al (2014) Plasma galectin-3 and heart failure outcomes in MADIT-CRT (Multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Card Fail 20:793\u2013799. https:\/\/doi.org\/10.1016\/j.cardfail.2014.07.018","journal-title":"J Card Fail"},{"key":"8207_CR86","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.healun.2008.02.018","volume":"27","author":"H Milting","year":"2008","unstructured":"Milting H, Ellinghaus P, Seewald M et al (2008) Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Hear Lung Transplant 27:589\u2013596. https:\/\/doi.org\/10.1016\/j.healun.2008.02.018","journal-title":"J Hear Lung Transplant"},{"key":"8207_CR87","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.healun.2012.11.011","volume":"32","author":"G Erkilet","year":"2013","unstructured":"Erkilet G, \u00d6zpeker C, B\u00f6thig D et al (2013) The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Hear Lung Transplant 32:221\u2013230. https:\/\/doi.org\/10.1016\/j.healun.2012.11.011","journal-title":"J Hear Lung Transplant"},{"key":"8207_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm8050570","volume":"8","author":"G Gagno","year":"2019","unstructured":"Gagno G, Padoan L, Stenner E et al (2019) Galectin 3 and galectin 3 binding protein improve the risk stratification after myocardial infarction. J Clin Med 8:1\u201314. https:\/\/doi.org\/10.3390\/jcm8050570","journal-title":"J Clin Med"},{"key":"8207_CR89","first-page":"595","volume":"64","author":"A Elena","year":"2016","unstructured":"Elena A, Ivan I, Elena A, Dmitry M (2016) Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis. Minerva Cardioangiol 64:595\u2013602","journal-title":"Minerva Cardioangiol"},{"key":"8207_CR90","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ahj.2014.02.011","volume":"167","author":"WC Meijers","year":"2014","unstructured":"Meijers WC, Januzzi JL, Adourian AS (2014) Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J 167:853\u20138604. https:\/\/doi.org\/10.1016\/j.ahj.2014.02.011","journal-title":"Am Heart J"},{"key":"8207_CR91","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/eurjhf\/hfs205","volume":"15","author":"IS Anand","year":"2013","unstructured":"Anand IS, Rector TS, Kuskowski M et al (2013) Baseline and serial measurements of galectin-3 in patients with heart failure\u202f: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 15:511\u2013518. https:\/\/doi.org\/10.1093\/eurjhf\/hfs205","journal-title":"Eur J Heart Fail"},{"key":"8207_CR92","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2143\/AC.71.2.3141849","volume":"71","author":"V Polat","year":"2017","unstructured":"Polat V, Bozcali E, Uygun T et al (2017) Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. Acta Cardiol 71:191\u2013197. https:\/\/doi.org\/10.2143\/AC.71.2.3141849","journal-title":"Acta Cardiol"},{"key":"8207_CR93","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1161\/ATVBAHA.114.304964","volume":"35","author":"G Maiolino","year":"2015","unstructured":"Maiolino G, Rossitto G, Pedon L et al (2015) Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 35:725\u2013732. https:\/\/doi.org\/10.1161\/ATVBAHA.114.304964","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"8207_CR94","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/onc.2016.306","volume":"36","author":"L Zhang","year":"2017","unstructured":"Zhang L, Wang P, Qin Y et al (2017) RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Oncogene 36:1297\u20131308. https:\/\/doi.org\/10.1038\/onc.2016.306","journal-title":"Oncogene"},{"key":"8207_CR95","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1073\/pnas.1202653110","volume":"110","author":"P Guha","year":"2013","unstructured":"Guha P, Kaptan E, Bandyopadhyaya G et al (2013) Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci U S A 110:5052\u20135057. https:\/\/doi.org\/10.1073\/pnas.1202653110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8207_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021811","author":"L Mirandola","year":"2011","unstructured":"Mirandola L, Yu Y, Chui K et al (2011) Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0021811","journal-title":"PLoS ONE"},{"key":"8207_CR97","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ygyno.2014.09.021","volume":"135","author":"L Mirandola","year":"2014","unstructured":"Mirandola L, Yu Y, Cannon MJ et al (2014) Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol 135:573\u2013579. https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.021","journal-title":"Gynecol Oncol"},{"key":"8207_CR98","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1177\/1534735418790382","volume":"17","author":"S Conti","year":"2018","unstructured":"Conti S, Vexler A, Hagoel L et al (2018) Modified citrus pectin as a potential sensitizer for radiotherapy in prostate cancer. Integr Cancer Ther 17:1225\u20131234. https:\/\/doi.org\/10.1177\/1534735418790382","journal-title":"Integr Cancer Ther"},{"key":"8207_CR99","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1210\/er.22.2.153","volume":"22","author":"G Pearson","year":"2001","unstructured":"Pearson G, Robinson F, Gibson TB et al (2001) Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22:153\u2013183. https:\/\/doi.org\/10.1210\/er.22.2.153","journal-title":"Endocr Rev"},{"key":"8207_CR100","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.molmed.2018.08.003","volume":"24","author":"RR Madsen","year":"2018","unstructured":"Madsen RR, Vanhaesebroeck B, Semple RK (2018) Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med 24:856\u2013870. https:\/\/doi.org\/10.1016\/j.molmed.2018.08.003","journal-title":"Trends Mol Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-08207-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-08207-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-08207-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T22:48:34Z","timestamp":1679870914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-08207-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["8207"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-08207-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animals rights"}},{"value":"This paper did not require informed consent from participants or animals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}